André Larente from DIAGNOS on Transforming Optometry and Expanding AI Capabilities

In a recent interview with InvestorNews host Tracy Weslosky, André Larente, President, CEO, and Director of DIAGNOS Inc. (TSXV: ADK | OTCQB: DGNOF), discussed the evolving role of optometrists in the face of advancing technology, particularly artificial intelligence (AI) in medical imaging. Larente highlighted how AI is transforming optometry from traditional roles, such as prescribing eyewear, to more complex tasks including monitoring diseases like diabetes and hypertension. He emphasized the imminent obsolescence of refraction equipment, predicting that “the role of the optometrist will change” to focus more on eye health and disease monitoring. This shift, according to Larente, positions optometrists closer to the medical field and specialists, enhancing their role in healthcare. Larente also shared insights on DIAGNOS’ pioneering efforts in AI for eye health, noting the company’s seven-year history of data collection across 14 countries involving roughly 400,000 patients. This extensive data has facilitated the development of predictive models for diseases affecting the retina. He elaborated on DIAGNOS’ strategic plans, including obtaining Health Canada and US FDA approvals for four new AI analysis modules aimed at expanding the company’s diagnostic capabilities beyond diabetic retinopathy. Larente stated, “These four tests… will actually multiply our revenue potential 4x’s….” underlining the strategic importance of these developments for DIAGNOS’ growth. The company’s commitment to compliance with new regulatory requirements for AI and ongoing partnerships, such as with EssilorLuxottica, further underscore its proactive approach in a competitive field.